Optimizing HIV Treatment Regimens
Researchers seek to determine the best antiretroviral treatment regimen for HIV.
Picking the right drug combinations for antiretroviral therapy (ART) for patients can be a challenge.
Researchers in Canada did a systematic review and network meta-analysis to suggest what combinations worked best in a study led by Steve Kanters, PhD, of Precision Health Economics in Vancouver, BC, Canada, which was published online in The Lancet HIV on September 6, 2016.
“The purpose of this study was to use a network meta-analysis to assess the comparative efficacy and safety of ART regimens available at present for the treatment of HIV in ART-naive patients,” the reviewers wrote.
They also note that a single analysis allows for an overview of an entire disease, which could inform clinical guidelines. In 2013, the World Health Organization (WHO) updated ART guidelines, and the authors said, “the recommended first-line ART regimen consists of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) and one non-nucleoside reverse transcriptase inhibitor.”
The researchers more specifically stated, “The combination of efavirenz, tenofovir disproxil fumarate, and emtricitabine or lamivudine is the preferred option.”
The reviewers included a total of 126 studies in their analysis, and report, “Overall trials were generally good quality with low risk of bias.”
After conducting multiple analyses, they wrote, “although efavirenz plus two NRTIs as a backbone remains a safe and efficacious regimen, other treatments are in some regards comparatively superior.”
For example, dolutegravir may be superior to efavirenz in the standard dose, and low-dose efavirenz is, in some cases, superior to standard dose efavirenz.
The reviewers wrote, “There are several implications and considerations related to these findings.” While WHO guidelines may need to updated, the reviewers point out that “complexity of care must also be considered.”
Ease of dosing and necessary screenings before administration of drugs could make different combinations of ART more complicated. The authors said, “Despite the improved efficacy and safety, issues exist regarding the feasibility of scaling up a first-line regimen containing dolutegravir,” including logistic and clinical problems.
“In conclusion, our systematic literature review found that among ART-naive patients, the use of an INSTI plus two NRTIs, particularly dolutegravir and raltegravir, has superior efficacy and tolerance to regimens of efavirenz plus two NRTIs, and that low-dose efavirenz is non-inferior to standard-dose efavirenz,” the reviewers wrote.